This page shows the latest Mosquirix news and features for those working in and with pharma, biotech and healthcare.
GSK's vaccine – also known as Mosquirix – is considered to have limited efficacy, but the sheer scale of the public health problem posed by malaria in some areas of the world
The results have been published in the journal Nature Medicine. That data looks pretty good when compared to trials of the Mosquirix malaria vaccine developed by GlaxoSmithKline (GSK) - which has already ... Mosquirix (formerly known as RTS, S) also
Mosquirix outside the EU.
The European regulator's Committee for Medicinal Products for Human Use (CHMP) gave Mosquirix a positive opinion for use outside the EU in young children alongside established antimalarial interventions. . ... The CHMP and GSK's biologics unit agreed
In addition, phase III trials started this quarter for Mosquirix, GSK's malaria vaccine. .
In November last year, it purchased 300 million doses of GlaxoSmithKline's investigational malaria vaccine, Mosquirix, to create demand for the product.
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
contain the adjuvant QS-21 Stimulon. In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA. GSK's malarial vaccine, Mosquirix which also contains
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...